No Data
No Data
Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating
DBS Maintains Amgen(AMGN.US) With Buy Rating
Amgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel Medication
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
U.S. Tweaks 2025 Medicare Price Negotiation Process
Amgen (NASDAQ:AMGN) Has A Somewhat Strained Balance Sheet
No Data
No Data
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.